Stock Market News
AstraZeneca secures European approval for asthma drug
Biopharmaceutical company AstraZeneca has received approval from the European Commission (EC) for its asthma medicine Fasenra.
Results from AstraZeneca's Phase III WINDWARD programme demonstrated a significantly reduced level of asthma exacerbations, improvements in lung function and reductions in oral corticosteroid use from baseline when weighted against placebos.
Fasenra, marketed as an add-on maintenance treatment for adult patients with severe eosinophilic asthma inadequately controlled by high-dose inhaled corticosteroids and long-acting beta-antagonists, was the first respiratory biologic medicine with an 8-week maintenance dosing schedule ever approved by the EC.
Sean Bohen, chief medical officer at AstraZeneca, said, "Fasenra is our first respiratory biologic medicine. Today's decision from the EC follows the recent approval of Fasenra in the US and is another positive step towards our ambition to transform care for severe asthma patients whose disease is driven by eosinophilic inflammation."
Tim Harrison, professor of asthma and respiratory medicine at the University of Nottingham, added: "Many patients with severe eosinophilic asthma experience debilitating symptoms and face increased risk of emergency room visits, hospitalisations and death, despite current treatments."
Fasenra had previously been granted US Food and Drug Administration (FDA) approval in November 2017.
As of 1610 GMT, AstraZeneca shares had lost 0.89% to 5,118.00p.
Results from AstraZeneca's Phase III WINDWARD programme demonstrated a significantly reduced level of asthma exacerbations, improvements in lung function and reductions in oral corticosteroid use from baseline when weighted against placebos.
Fasenra, marketed as an add-on maintenance treatment for adult patients with severe eosinophilic asthma inadequately controlled by high-dose inhaled corticosteroids and long-acting beta-antagonists, was the first respiratory biologic medicine with an 8-week maintenance dosing schedule ever approved by the EC.
Sean Bohen, chief medical officer at AstraZeneca, said, "Fasenra is our first respiratory biologic medicine. Today's decision from the EC follows the recent approval of Fasenra in the US and is another positive step towards our ambition to transform care for severe asthma patients whose disease is driven by eosinophilic inflammation."
Tim Harrison, professor of asthma and respiratory medicine at the University of Nottingham, added: "Many patients with severe eosinophilic asthma experience debilitating symptoms and face increased risk of emergency room visits, hospitalisations and death, despite current treatments."
Fasenra had previously been granted US Food and Drug Administration (FDA) approval in November 2017.
As of 1610 GMT, AstraZeneca shares had lost 0.89% to 5,118.00p.
Related share prices |
---|
AstraZeneca (AZN) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price